Hartford Hospital, Hartford, CT, USA.
Analysis Group Inc., Montréal, QC, Canada.
Curr Med Res Opin. 2023 Sep;39(9):1279-1286. doi: 10.1080/03007995.2023.2247967. Epub 2023 Aug 28.
To compare the risk of stroke and systemic embolism (SE) among patients with nonvalvular atrial fibrillation (NVAF) who abandoned their first direct oral anticoagulant (DOAC) fill ("abandoners") relative to patients who continued DOACs beyond the first fill ("continuers").
In this retrospective longitudinal study, adults with NVAF prescribed DOACs were selected from Symphony Health, an ICON plc Company, PatientSource, 1 April 2017 to 31 October 2020. A 90-day landmark period following the first DOAC fill was used to classify patients as abandoners or continuers. Inverse probability of treatment weighting was used to balance baseline characteristics between cohorts. Time to ischemic stroke/SE was described and compared between cohorts using weighted Kaplan-Meier and Cox proportional hazard models from the end of the landmark period until end of clinical activity or data.
After weighting, 200,398 and 211,352 patients comprised the abandoner and continuer cohorts, respectively. The mean duration of follow-up was 14.9 and 15.7 months, respectively. At 12 months of follow-up, the probability of ischemic stroke/SE was 1.34% in the abandoner cohort and 1.00% in the continuer cohort; the risk of ischemic stroke/SE was 35% higher in the abandoner versus continuer cohort (hazard ratio [95% confidence interval] = 1.35 [1.20, 1.51]; < 0.0001).
Patients with NVAF who abandoned the first DOAC fill had significantly higher risk of ischemic stroke/SE compared to patients who continued therapy beyond the first fill. There is an unmet need for better access to DOACs so that the long-term risk of poor outcomes may be minimized.
比较放弃首次直接口服抗凝剂(DOAC)填充的非瓣膜性心房颤动(NVAF)患者与继续 DOAC 治疗超过首次填充的患者之间中风和全身性栓塞(SE)的风险。
在这项回顾性纵向研究中,从 Symphony Health,一家 ICON plc 公司,PatientSource 中选择了 NVAF 患者,处方了 DOAC,时间为 2017 年 4 月 1 日至 2020 年 10 月 31 日。使用首次 DOAC 填充后的 90 天里程碑期将患者分为放弃者和继续者。使用逆概率治疗权重在队列之间平衡基线特征。使用加权 Kaplan-Meier 和 Cox 比例风险模型,从里程碑期末到临床活动或数据结束,描述并比较队列之间的缺血性中风/SE 时间。
加权后,放弃者和继续者队列分别包括 200398 名和 211352 名患者。平均随访时间分别为 14.9 个月和 15.7 个月。在 12 个月的随访中,放弃者队列中缺血性中风/SE 的概率为 1.34%,继续者队列中为 1.00%;与继续者相比,放弃者中风/SE 的风险高 35%(风险比[95%置信区间]为 1.35[1.20,1.51];<0.0001)。
与继续治疗超过首次填充的患者相比,放弃首次 DOAC 填充的 NVAF 患者中风/SE 的风险显著增加。需要更好地获得 DOAC 治疗,以最大程度地降低长期不良结局的风险。